All In Biotech

Drug Trial Radar · NCT06304805

TGRX-326 Pharmacokinetic Food Effect Bioavailability Study

A Randomized, Open-label, Single-dose, 3-cycle, 6-sequence, Crossover Study Evaluating Food Effect on Pharmacokinetic Profiles of TGRX-326 in Chinese Healthy Subjects and Effect of Drug Specification on Bioavailability in Human

Last checked: Nov 19, 2026Latest source record: May 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Dec 13, 2023

Primary completion

Jan 12, 2024

Study completion Jan 19, 2024

Sponsor

Lead sponsor
Shenzhen TargetRx Co., Ltd.Industry
Sponsor type
Industry
Collaborators
The First Affiliated Hospital of Bengbu Medical University
First posted
Mar 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A study evaluating the effects of food intake on the pharmacokinetic (PK) profiles of TGRX-326 and the effect of different drug specifications on human bioavailability for TGRX-326, a drug indicated for non-small cell lung cancer treatment

Conditions

  • Non Small Cell Lung Cancer

Interventions

  • cycle 1: treatment drugDrug

    for cycle 1 treatment: participants are given the oral treatment specification (60 mg \*1 pill)

  • cycle 1: reference drugDrug

    for cycle 1 treatment: participants are given the oral reference specification (5 mg \*2 pills + 25 mg \* 2 pills)

  • cycle 1: fastedBehavioral

    for cycle 1 treatment: participants are asked to take the drug fasted

  • cycle 1: foodBehavioral

    for cycle 1 treatment: participants are asked to take the drug after food intake

  • cycle 2: treatment drugDrug

    for cycle 2 treatment: participants are given the oral treatment specification (60 mg \*1 pill)

  • cycle 2: reference drugDrug

    for cycle 2 treatment: participants are given the oral reference specification (5 mg \*2 pills + 25 mg \* 2 pills)

  • cycle 2: fastedBehavioral

    for cycle 2 treatment: participants are asked to take the drug fasted

  • cycle 2: foodBehavioral

    for cycle 2 treatment: participants are asked to take the drug after food intake

  • cycle 3: treatment drugDrug

    for cycle 3 treatment: participants are given the oral treatment specification (60 mg \*1 pill)

  • cycle 3: reference drugDrug

    for cycle 3 treatment: participants are given the oral reference specification (5 mg \*2 pills + 25 mg \* 2 pills)

  • cycle 3: fastedBehavioral

    for cycle 3 treatment: participants are asked to take the drug fasted

  • cycle 3: foodBehavioral

    for cycle 3 treatment: participants are asked to take the drug after food intake

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma CmaxTime frame: During treatment period on Day 1 of each of three cycles (each cycle is one day, and there is a 10-day washout period between two cycles)
  2. Plasma AUC(0-t)Time frame: During treatment period on Day 1 of each of three cycles (each cycle is one day, and there is a 10-day washout period between two cycles)
  3. Plasma AUC(0-inf)Time frame: During treatment period on Day 1 of each of three cycles (each cycle is one day, and there is a 10-day washout period between two cycles)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • First Affiliated Hospital Bengbu Medical College

    Bengbu, Anhui, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.